Medical device firm Cheetah Medical has commercially introduced its FDA-cleared and CE-marked Starling SV noninvasive hemodynamic monitoring system.
The hemodynamic monitoring system will provide data for real-time clinical decision-making and optimized patient outcomes across a hospital’s continuum of care.
Cheetah Medical chief physician executive Douglas Hansell said: "Until the introduction of Cheetah Nicom, the only choices for obtaining accurate and continuous hemodynamic measurements were invasive technologies that carry their own set of risks.
"Now, with the Starling SV or Cheetah Nicom, a clinician has all of the important parameters continuously at his or her disposal.
Clinical status and the effect of IV fluids can be monitored at any time and treatment modified accordingly."
According to the company, the Starling SV system has a sensitivity of 94% and specificity of 100% for predicting IV-fluids responsiveness in critical care situations and it predicts IV-fluids responsiveness similarly to invasive esophageal Doppler and other invasive modalities.
The system reduces the risk of infection and vascular damage associated with older, invasive technologies requiring arterial or central lines and is independently validated against pulmonary artery catheter.
It is EMR-compatible and offers continuous information on cardiac index, cardiac output, strokevolume index, stroke volume, total peripheral resistance and other vitally important parameters.